Lilly’s GLP-1 medications will soon be covered by CVS, potentially opening access for millions of Americans

That means millions more Americans may get access to Lilly’s new GLP-1 pill Foundayo or the GLP-1 injection Zepbound.

After backlash from patients, CVS restores coverage of popular weight-loss drug Zepbound

CVS Caremark, one of America’s most powerful pharmacy benefit managers, will begin covering more GLP-1 medications again ...
CNN

A pharmacy benefit manager stopped covering a GLP-1 for obesity. Now there’s a lawsuit

A class-action lawsuit has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lilly’s blockbuster GLP-1 drug to treat obesity. When the major pharmacy benefit manager ...

CVS adds weight-loss drug, Zepbound, back to preferred coverage

In a reversal from last year, CVS will begin covering Eli Lilly's Zepbound and Foundayo in its standard prescription plan, a win for GLP-1 patients.

Zepbound vs. Wegovy For Weight Loss: What’s The Difference?

If you’re weighing the option of Wegovy versus Zepbound for weight loss, here’s how the two medications compare in terms of ...

What to Know About Zepbound (Tirzepatide), the Mounjaro-Like Weight Loss Drug

Tirzepatide, the active ingredient in Zepbound and Mounjaro, is the first drug in a family of medicines that target two ...